Join        Login             Stock Quote

New drug approved for erectile dysfunction

Saturday, April 28, 2012 1:37 AM

MOUNTAIN VIEW, Calif., April 28 (UPI) -- The U.S. Food and Drug Administration has approved Stendra, or avanafil, tablets for the treatment of erectile dysfunction in men, officials said.

Peter Tam, president of the biopharmaceutical company Vivus, said the approval is the first for nearly a decade to help treat the 30 million U.S. men with erectile dysfunction.

"Patients and treating physicians continue to report significant dissatisfaction with current treatments of erectile dysfunction," Tam said in a statement. "We believe that the PDE5 selectivity and absorption profile of Stendra make it an important new treatment option for many men with erectile dysfunction."

More than 1,200 men with erectile dysfunction participated in clinical studies evaluating the efficacy and safety of Stendra, and significant improvement in erectile function was observed for all doses -- in 50milligrams, 100mg and 200mg -- compared to placebo.

It is recommended that Stendra should be taken approximately 30 minutes before sexual activity and should not be taken more than once per day.

Erectile dysfunction affects an estimated 52 percent of men between the ages of 40 and 70, Tam said.

(Source: UPI )
(Source: Quotemedia)


Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.